Physician profile
Jaye Krubally
NPI 1093132482
$3,119.70
in general payments reported to CMS, 2019-2025
24 companies · $618 in 2025
The $618 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $649 · 2023: $927 · 2024: $455 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.26 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $583.78 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $260.47 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $202.09 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.75 | 2023-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $153.99 | 2022-2024 | Quviviq |
| Alkermes, INC. | $141.85 | 2024-2025 | Lybalvi, Aristada |
| Cumberland Pharmaceuticals, INC. | $83.48 | 2022-2023 | Kristalose |
| Acadia Pharmaceuticals INC | $67.24 | 2025 | Daybue |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.20 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $58.63 | 2021-2024 | Mounjaro |
| Evoke Pharma, INC. | $55.05 | 2021-2022 | |
| Genentech USA, INC. | $52.95 | 2021-2022 | |
| Abbott Laboratories | $41.72 | 2024-2025 | Freestyle Libre 3 |
| Optinose US, INC. | $38.37 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $34.83 | 2023 | Rexulti |
| Novo Nordisk INC | $33.58 | 2021-2023 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $22.62 | 2024 | |
| Pfizer INC. | $18.64 | 2024 | |
| Cipher Pharmaceuticals US LLC | $17.65 | 2025 | Natroba, Spinosad |
| Almatica Pharma LLC | $16.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2023 | Livalo |
| Amgen INC. | $13.81 | 2022 | |
| Merck Sharp & Dohme LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaye Krubally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.